Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
37
TAK Quote, Financials, Valuation and Earnings
Last price:
$13.17
Seasonality move
:
6.06%
Day range:
$13.09 - $13.19
52-week range:
$12.58 - $15.08
Dividend yield:
4.7%
P/E ratio:
21.79x
P/S ratio:
1.39x
P/B ratio:
0.86x
Volume:
968.4K
Avg. volume:
1.8M
1-year change:
-6.26%
Market cap:
$41.8B
Revenue:
$29.5B
EPS (TTM):
$0.60
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical
|
$7.2B | -- | 0.1% | -- | $16.03 |
|
ALPMY
Astellas Pharma
|
-- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China)
|
-- | -- | -- | -- | $28.11 |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical
|
$13.17 | $16.03 | $41.8B | 21.79x | $0.33 | 4.7% | 1.39x |
|
ALPMY
Astellas Pharma
|
$9.65 | -- | $17.3B | 165.47x | $0.25 | 4.88% | 1.52x |
|
HCM
HUTCHMED (China)
|
$14.30 | $28.11 | $2.4B | 30.00x | $0.00 | 0% | 5.93x |
|
HLOSF
Healios KK
|
$1.35 | -- | $121.7M | -- | $0.00 | 0% | 32.00x |
|
PPTDF
PeptiDream
|
$17.15 | -- | $2.2B | 20.38x | $0.00 | 0% | 7.14x |
|
SOLTF
Nxera Pharma
|
$6.16 | -- | $553.6M | -- | $0.00 | 0% | 2.79x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical
|
42.19% | 0.312 | 78.44% | 0.68x |
|
ALPMY
Astellas Pharma
|
36.57% | -0.037 | -- | 0.71x |
|
HCM
HUTCHMED (China)
|
9.99% | -0.098 | 2.79% | 2.39x |
|
HLOSF
Healios KK
|
65.07% | -0.707 | 34.39% | 1.33x |
|
PPTDF
PeptiDream
|
25.75% | -2.667 | 6.45% | 3.28x |
|
SOLTF
Nxera Pharma
|
48.92% | 1.984 | 55.24% | 3.73x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical
|
$5.3B | $1.8B | 2.37% | 4.01% | 15.97% | $1.3B |
|
ALPMY
Astellas Pharma
|
$2.5B | $306.7M | 0.66% | 0.97% | 11.62% | $366.7M |
|
HCM
HUTCHMED (China)
|
-- | -- | -5.04% | -5.49% | -- | -- |
|
HLOSF
Healios KK
|
$2.8M | -$1.8M | -55.94% | -137.21% | -24.5% | -$4.8M |
|
PPTDF
PeptiDream
|
$17.4M | -$854.5K | 24.02% | 34.66% | -1.5% | $173.8M |
|
SOLTF
Nxera Pharma
|
$48.9M | $5.4M | -2.75% | -5.58% | 11.44% | $10.3M |
Takeda Pharmaceutical vs. Competitors
-
Which has Higher Returns TAK or ALPMY?
Astellas Pharma has a net margin of 7.83% compared to Takeda Pharmaceutical's net margin of 7.95%. Takeda Pharmaceutical's return on equity of 4.01% beat Astellas Pharma's return on equity of 0.97%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical66.47% $0.19 $83.8B ALPMYAstellas Pharma80.74% $0.13 $16.6B -
What do Analysts Say About TAK or ALPMY?
Takeda Pharmaceutical has a consensus price target of $16.03, signalling upside risk potential of 20.8%. On the other hand Astellas Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than Astellas Pharma, analysts believe Takeda Pharmaceutical is more attractive than Astellas Pharma.
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical3 1 0 ALPMYAstellas Pharma0 0 0 -
Is TAK or ALPMY More Risky?
Takeda Pharmaceutical has a beta of 0.498, which suggesting that the stock is 50.209% less volatile than S&P 500. In comparison Astellas Pharma has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.161%.
-
Which is a Better Dividend Stock TAK or ALPMY?
Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.7%. Astellas Pharma offers a yield of 4.88% to investors and pays a quarterly dividend of $0.25 per share. Takeda Pharmaceutical pays 199.34% of its earnings as a dividend. Astellas Pharma pays out 684.38% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TAK or ALPMY?
Takeda Pharmaceutical quarterly revenues are $7.9B, which are larger than Astellas Pharma quarterly revenues of $3B. Takeda Pharmaceutical's net income of $619.7M is higher than Astellas Pharma's net income of $241.2M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 21.79x while Astellas Pharma's PE ratio is 165.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.39x versus 1.52x for Astellas Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical1.39x 21.79x $7.9B $619.7M ALPMYAstellas Pharma1.52x 165.47x $3B $241.2M
-
Which has Higher Returns TAK or HCM?
HUTCHMED (China) has a net margin of 7.83% compared to Takeda Pharmaceutical's net margin of --. Takeda Pharmaceutical's return on equity of 4.01% beat HUTCHMED (China)'s return on equity of -5.49%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical66.47% $0.19 $83.8B HCMHUTCHMED (China)-- -- $834.1M -
What do Analysts Say About TAK or HCM?
Takeda Pharmaceutical has a consensus price target of $16.03, signalling upside risk potential of 20.8%. On the other hand HUTCHMED (China) has an analysts' consensus of $28.11 which suggests that it could grow by 96.54%. Given that HUTCHMED (China) has higher upside potential than Takeda Pharmaceutical, analysts believe HUTCHMED (China) is more attractive than Takeda Pharmaceutical.
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical3 1 0 HCMHUTCHMED (China)9 2 0 -
Is TAK or HCM More Risky?
Takeda Pharmaceutical has a beta of 0.498, which suggesting that the stock is 50.209% less volatile than S&P 500. In comparison HUTCHMED (China) has a beta of 0.781, suggesting its less volatile than the S&P 500 by 21.86%.
-
Which is a Better Dividend Stock TAK or HCM?
Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.7%. HUTCHMED (China) offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 199.34% of its earnings as a dividend. HUTCHMED (China) pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TAK or HCM?
Takeda Pharmaceutical quarterly revenues are $7.9B, which are larger than HUTCHMED (China) quarterly revenues of --. Takeda Pharmaceutical's net income of $619.7M is higher than HUTCHMED (China)'s net income of --. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 21.79x while HUTCHMED (China)'s PE ratio is 30.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.39x versus 5.93x for HUTCHMED (China). Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical1.39x 21.79x $7.9B $619.7M HCMHUTCHMED (China)5.93x 30.00x -- --
-
Which has Higher Returns TAK or HLOSF?
Healios KK has a net margin of 7.83% compared to Takeda Pharmaceutical's net margin of -107.23%. Takeda Pharmaceutical's return on equity of 4.01% beat Healios KK's return on equity of -137.21%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical66.47% $0.19 $83.8B HLOSFHealios KK86.35% -$0.04 $57.8M -
What do Analysts Say About TAK or HLOSF?
Takeda Pharmaceutical has a consensus price target of $16.03, signalling upside risk potential of 20.8%. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than Healios KK, analysts believe Takeda Pharmaceutical is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical3 1 0 HLOSFHealios KK0 0 0 -
Is TAK or HLOSF More Risky?
Takeda Pharmaceutical has a beta of 0.498, which suggesting that the stock is 50.209% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock TAK or HLOSF?
Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.7%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 199.34% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TAK or HLOSF?
Takeda Pharmaceutical quarterly revenues are $7.9B, which are larger than Healios KK quarterly revenues of $3.2M. Takeda Pharmaceutical's net income of $619.7M is higher than Healios KK's net income of -$3.4M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 21.79x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.39x versus 32.00x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical1.39x 21.79x $7.9B $619.7M HLOSFHealios KK32.00x -- $3.2M -$3.4M
-
Which has Higher Returns TAK or PPTDF?
PeptiDream has a net margin of 7.83% compared to Takeda Pharmaceutical's net margin of -5.57%. Takeda Pharmaceutical's return on equity of 4.01% beat PeptiDream's return on equity of 34.66%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical66.47% $0.19 $83.8B PPTDFPeptiDream47.13% -$0.02 $551.4M -
What do Analysts Say About TAK or PPTDF?
Takeda Pharmaceutical has a consensus price target of $16.03, signalling upside risk potential of 20.8%. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than PeptiDream, analysts believe Takeda Pharmaceutical is more attractive than PeptiDream.
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical3 1 0 PPTDFPeptiDream0 0 0 -
Is TAK or PPTDF More Risky?
Takeda Pharmaceutical has a beta of 0.498, which suggesting that the stock is 50.209% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.826, suggesting its less volatile than the S&P 500 by 17.389%.
-
Which is a Better Dividend Stock TAK or PPTDF?
Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.7%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 199.34% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TAK or PPTDF?
Takeda Pharmaceutical quarterly revenues are $7.9B, which are larger than PeptiDream quarterly revenues of $36.8M. Takeda Pharmaceutical's net income of $619.7M is higher than PeptiDream's net income of -$2.1M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 21.79x while PeptiDream's PE ratio is 20.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.39x versus 7.14x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical1.39x 21.79x $7.9B $619.7M PPTDFPeptiDream7.14x 20.38x $36.8M -$2.1M
-
Which has Higher Returns TAK or SOLTF?
Nxera Pharma has a net margin of 7.83% compared to Takeda Pharmaceutical's net margin of 12.96%. Takeda Pharmaceutical's return on equity of 4.01% beat Nxera Pharma's return on equity of -5.58%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical66.47% $0.19 $83.8B SOLTFNxera Pharma78.44% $0.09 $928.9M -
What do Analysts Say About TAK or SOLTF?
Takeda Pharmaceutical has a consensus price target of $16.03, signalling upside risk potential of 20.8%. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than Nxera Pharma, analysts believe Takeda Pharmaceutical is more attractive than Nxera Pharma.
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical3 1 0 SOLTFNxera Pharma0 0 0 -
Is TAK or SOLTF More Risky?
Takeda Pharmaceutical has a beta of 0.498, which suggesting that the stock is 50.209% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.337, suggesting its less volatile than the S&P 500 by 66.345%.
-
Which is a Better Dividend Stock TAK or SOLTF?
Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.7%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 199.34% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TAK or SOLTF?
Takeda Pharmaceutical quarterly revenues are $7.9B, which are larger than Nxera Pharma quarterly revenues of $62.4M. Takeda Pharmaceutical's net income of $619.7M is higher than Nxera Pharma's net income of $8.1M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 21.79x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.39x versus 2.79x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical1.39x 21.79x $7.9B $619.7M SOLTFNxera Pharma2.79x -- $62.4M $8.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
